Viral vectors having enhanced effectiveness with reduced virulence

   
   

The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising the recombinant vaccinia virus are also provided.

La actual invención proporciona métodos de uso del virus recombinant del vaccinia de el cual la región que codificaba los aminoácidos del N-terminal 83 o 54 del producto del gene de E3L se ha suprimido, o los aminoácidos en las posiciones 44 y 66 han sido transformados. Las composiciones que abarcan el virus recombinant del vaccinia también se proporcionan.

 
Web www.patentalert.com

< Use of parovirus capsid particles in the inhibition of cell proliferation and migration

< Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy

> Virulence genes and proteins, and their use

> Compositions and methods for enhancing corticosteroid delivery

~ 00157